JPRN-UMIN000029668
Not yet recruiting
未知
The exploratory study for the efficacy and the safety of Rikkunshito on symptoms of indigestion in the patients with Functional Heartburn - The efficacy of Rikkunshito on indigestion in the patients with Functional Heartburn
ippon Medical School Graduate School of Medicine0 sites20 target enrollmentOctober 24, 2017
ConditionsFunctional Heartburn
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Functional Heartburn
- Sponsor
- ippon Medical School Graduate School of Medicine
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients diagnosed with Eosinophilic esophagitis(EoE) 2\)Patients diagnosed with Esophageal Motility disorders by High\-Resolution manometry. 3\)Patients who had 50% or more of Symptom Index by 24\-hour Esophageal Impedance and PH monitoring. 4\)Patients diagnosed with Reflux esophagitis(RE)(Los Angeles classification,\>\=Grade A)by upper endoscopy. 5\)History of upper GI resection 6\)Confirmed presence of ulcer (excluding scars) or malignant tumor in the upper GI. 7\)Suspected organic hepatic/biliary/pancreatic disorders such as gallstone, hepatitis, and pancreatitis 8\)History of allergic reactions to Kampo medicines. 9\)Patients who were administered KAMPO medicine 4 weeks before entry. 10\)Receiving or scheduled to receive an agent that is being developed. 11\)Presence of serious complications (liver, kidney, heart, or blood disease or metabolic disease). 12\)Pregnant or lactating women or those who are planning to conceive during the study period. 13\)Considered ineligible to participate by principal investigator or sub\-investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The exploratory study for the efficacy and the safety of Hangeshashinto on symptoms of heartburn /belch in the patients with gastroesophageal reflux disease (GERD)GERDJPRN-UMIN000021251Osaka Medical College80
Completed
Not Applicable
The exploratory study for the efficacy and the safety of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.Abdominal pain and abdominal fullness feeling in the patients with fecal incontinenceJPRN-UMIN000030252Medical Corporation Seiaikai, Gion Usshita Hospital50
Completed
Not Applicable
The exploratory study for the efficacy and the safety of rikkunshito on symptoms of upper gastrointestinal tract in the patients with gastroesophageal reflux disease (GERD)GERD patientsJPRN-UMIN000003092Chiba University Hospital100
Recruiting
Phase 2
Exploratory Study to Evaluate the Efficacy and Safety of Baricitinib in Interstitial Pneumonia Associated with Anti-MDA5 Antibody-Positive DermatomyositisInterstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositisJPRN-jRCTs031220641Fujio Keishi5
Active, not recruiting
Phase 1
Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical ventilatioAcquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient.MedDRA version: 20.0Level: PTClassification code 10077255Term: Intensive care unit acquired weaknessSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Not possible to specifyEUCTR2021-002329-56-ESSociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)200